Archive – Page 8 – PULMONARY HYPERTENSION

Alveolar Septal Width as a Predictor of Chronic Lung Allograft Dysfunction and Survival After Lung Transplantation, Journal of Clinical Medicine, September 9, 2025

Researchers may have found a way to predict which lung transplant patients will develop serious complications before symptoms appear. In a study titled “Increase in Alveolar Septal Width Is a Histological Predictor of Chronic Lung Allograft Dysfunction and Survival in Lung Transplant Recipients—A Longitudinal Study” the authors measure the thickness of air sac walls in lung […]

Alveolar Septal Width as a Predictor of Chronic Lung Allograft Dysfunction and Survival After Lung Transplantation, Journal of Clinical Medicine, September 9, 2025 Read Post »

New study reveals how BMP-9 regulates lung vessels, opening doors for future pulmonary arterial hypertension therapies, new findings from a Franco-German study, Proceedings of the National Academy of Sciences of the USA (PNAS), July 2025

Pulmonary arterial hypertension (PAH) happens when the blood vessels in the lungs become too narrow and stiff. This raises pressure in the lungs and puts strain on the heart. In a collaborative study, scientists from Inserm and Université Paris-Saclay in France, together with researchers from the Institute for Lung Health (ILH) in Germany, discovered

New study reveals how BMP-9 regulates lung vessels, opening doors for future pulmonary arterial hypertension therapies, new findings from a Franco-German study, Proceedings of the National Academy of Sciences of the USA (PNAS), July 2025 Read Post »

The Rising Crisis of Meth-Associated Pulmonary Hypertension in America, a special edition series of the phaware podcast “I’m aware that I am rare”.

phaware® global association announces the launch of an impactful new special edition series of our acclaimed podcast, “I’m Aware That I’m Rare,“ shining a spotlight on the urgent and growing crisis of methamphetamine-associated pulmonary hypertension (Meth-PAH). The six-episode series, premiering September 16 and running through October 21, kicks off our 10th season and leads up to November’s Pulmonary Hypertension Awareness Month with

The Rising Crisis of Meth-Associated Pulmonary Hypertension in America, a special edition series of the phaware podcast “I’m aware that I am rare”. Read Post »

“How to empower yourself & others”, an 11-part series to support pulmonary hypertension patients created by the IDDI Patient Engagement and Empowerment Workstream of the Pulmonary Vascular Research Institute, PVRI

The IDDI Patient Engagement and Empowerment Workstream of the Pulmonary Vascular Research Institute has created an 11-part series to support people living with pulmonary hypertension, and for their families and carers. The series is designed to help people living with pulmonary hypertension to feel more informed, confident and empowered. Empowerment means gaining the knowledge, skills,

“How to empower yourself & others”, an 11-part series to support pulmonary hypertension patients created by the IDDI Patient Engagement and Empowerment Workstream of the Pulmonary Vascular Research Institute, PVRI Read Post »

Allrock Bio Raises $50M to advance pulmonary arterial hypertension (PAH) and pulmonary hypertension due to interstitial lung disease (PH-ILD) Treatment ROC-101 into Phase 2a Trials

Allrock Bio raised $50M to fund Phase 2a trials of ROC-101, an oral treatment for pulmonary hypertension. The ROCSTAR trial will test ROC-101 combined with standard therapies in pulmonary arterial hypertension (PAH) and pulmonary hypertension due to underlying interstitial lung disease (PH-ILD) patients, starting late 2025. ROC-101 blocks ROCK1 and ROCK2 proteins to reduce inflammation,

Allrock Bio Raises $50M to advance pulmonary arterial hypertension (PAH) and pulmonary hypertension due to interstitial lung disease (PH-ILD) Treatment ROC-101 into Phase 2a Trials Read Post »

Data on investigational treprostinil transdermal patch system to be presented at professional symposium organised by the US Pulmonary Hypertension Association, September 18-20, 2025

Corsair Pharma will present preclinical data on their TRX-248 transdermal patch at the Pulmonary Hypertension Professional Network Symposium (PHPPN), Sept 18-20, 2025. The once-daily patch delivers treprostinil for pulmonary arterial hypertension treatment. These data provide additional support for the clinical program which is currently in a first-in-human Phase 1 study. The transdermal patch has the

Data on investigational treprostinil transdermal patch system to be presented at professional symposium organised by the US Pulmonary Hypertension Association, September 18-20, 2025 Read Post »

Understanding Risk Assessment in Pulmonary Arterial Hypertension, International Society for Heart and Lung Transplant ISHLT Consensus Statement, The Journal of Heart and Lung Transplantation – September 05, 2025

What is pulmonary arterial hypertension and why does risk assessment matter? Pulmonary arterial hypertension is a rare, serious disease where the blood vessels in thelungs become too narrow. This makes the right side of the heart work harder, which overtime can lead to heart failure. Because it can progress quickly, doctors use risk assessment (sometimes

Understanding Risk Assessment in Pulmonary Arterial Hypertension, International Society for Heart and Lung Transplant ISHLT Consensus Statement, The Journal of Heart and Lung Transplantation – September 05, 2025 Read Post »

Returning from the World Transplant Games full of emotions, Maggy Surace, double lung transplant recipient, President of the French Pulmonary Hypertension Association HTaPFrance

Maggy Surace is the President of the French Pulmonary Hypertension Association HTaPFrance and a double lung transplant recipient. She was among the 1,513 athletes from 50 different countries participating in the World Transplant Games in Dresden, Germany on August 17-24, 2025. Maggy trained for over 4 months for the swimming and athletics events. She left

Returning from the World Transplant Games full of emotions, Maggy Surace, double lung transplant recipient, President of the French Pulmonary Hypertension Association HTaPFrance Read Post »

The World Transplant Games 2025, August 17-24 2025, Dresden, Germany

The World Transplant Games are a remarkable international multisport event that brings together transplant recipients, living donors, donor families, supporters and friends to celebrate the Gift of Life and show the positive impact of organ donation. The games span seven days, featuring a program of both high-exertion and low-impact sports, with 2,500 participants, families, and

The World Transplant Games 2025, August 17-24 2025, Dresden, Germany Read Post »

Deep Learning Models Can Identify Pulmonary Arterial Hypertension associated with Congenital Heart Disease (CHD-PAH) on Routine Chest X-Ray, The Cardiology Advisor, September 5, 2025

Key point: The deep learning-based chest X-ray model for pulmonary hypertension detection, CXR-PH-Net, proved particularly sensitive in identifying in early-stage/mild pulmonary hypertension. Researchers in China developed artificial intelligence programs that can analyze chest X-rays to detect pulmonary hypertension by training computer programs using chest X-rays from over 6,700 patients in Beijing hospitals, comparing those with and

Deep Learning Models Can Identify Pulmonary Arterial Hypertension associated with Congenital Heart Disease (CHD-PAH) on Routine Chest X-Ray, The Cardiology Advisor, September 5, 2025 Read Post »

TETON-2 Pivotal Study of Tyvaso® Meets Primary Endpoint for the Treatment of Idiopathic Pulmonary Fibrosis, September 2, 2025

United Therapeutics has announced that the pivotal TETON-2 study of nebulized Tyvaso® (treprostinil) for the treatment of idiopathic pulmonary fibrosis (WHO Group III) met its primary endpoint—and several key secondary endpoints—with statistical significance. Read more on the press release at this link

TETON-2 Pivotal Study of Tyvaso® Meets Primary Endpoint for the Treatment of Idiopathic Pulmonary Fibrosis, September 2, 2025 Read Post »

Patient empowerment and Patient Reported Outcome Measures (PROMs) highlighted at the “World Symposium on Pulmonary Hypertension Updates” conference, Bologna, July 3-5, 2025

Pisana Ferrari, Secretary General of the Alliance for Pulmonary Hypertension and President of the Italian Pulmonary Hypertension Association AIPI, was invited to deliver the opening presentation on patient perspectives and empowerment at the “World Symposium on Pulmonary Hypertension Updates” conference in Bologna on July 3-5, 2025. Unfortunately, due to health issues, she had to withdraw

Patient empowerment and Patient Reported Outcome Measures (PROMs) highlighted at the “World Symposium on Pulmonary Hypertension Updates” conference, Bologna, July 3-5, 2025 Read Post »

The “Cardiac community”, a patient advocacy group in Nigeria, launches initiative to support patients who can’t pay for their medications

The “Cardiac Community” was founded in 2018 by Ayotunde Omitogun, a pulmonary arterial hypertension patients diagnosed in 2013. It is a community of people passionate about fighting heart disease in Nigeria who engage in heart disease and health awareness, fundraising, advocacy and support for people living with heart disease in Nigeria. The Community has set

The “Cardiac community”, a patient advocacy group in Nigeria, launches initiative to support patients who can’t pay for their medications Read Post »

A review of the book “The Patient Priority”, authored by Stefan Larsson, Jennifer Clawson and Joshua Kellar, August 2025

Steven Gijssels is Chair of the Patient Expert Center in Belgium. He has recently published a review of the book “The Patient Priority” by Stefan Larsson, Jennifer Clawson and Joshua Kellar, three Boston Consulting Group consultants. The book calls for integrated care, more efficient reimbursement models, and outcome-focused evaluations of healthcare interventions. Tracking patient outcomes

A review of the book “The Patient Priority”, authored by Stefan Larsson, Jennifer Clawson and Joshua Kellar, August 2025 Read Post »

August 2025 edition of “Rundbrief”, the official magazine of the German pulmonary hypertension association ph e.v., is now out

The German pulmonary hypertension association ph e.v. has published the August edition of its magazine “Rundbrief”, very rich in content as always. Key topics covered include: Research and Medical Advances: Clinical Practice: Professional Development: PDF In German available here

August 2025 edition of “Rundbrief”, the official magazine of the German pulmonary hypertension association ph e.v., is now out Read Post »

Tool identifies degree of 1-year mortality risk in patients with pulmonary hypertension due to underlying lung disease, Healio, August 26, 2025

Risk scores designed for pulmonary arterial hypertension (Group I of the World Health Organisation classification for pulmonary hypertension) do not adequately account for the unique pathophysiology seen in patients whose pulmonary hypertension arises from underlying lung disease (Group III of the World Health Organisation (WHO) classification). This is the rationale behind a retrospective study of

Tool identifies degree of 1-year mortality risk in patients with pulmonary hypertension due to underlying lung disease, Healio, August 26, 2025 Read Post »

Transplants are still too difficult to schedule for pulmonary hypertension patients, Anna Lisabeth Jeter, Pulmonary Hypertension News, August 28, 2025

Anna Jeter, is an artist, writer and photographer living in Excelsior, Minnesota, USA. She was diagnosed with pulmonary arterial hypertension at the age of 4 but only received a heart-lung transplant 19 years later, in 2018. In a recent article for Pulmonary Hypertension News she expresses gratitude for surviving long enough to receive the transplant

Transplants are still too difficult to schedule for pulmonary hypertension patients, Anna Lisabeth Jeter, Pulmonary Hypertension News, August 28, 2025 Read Post »

Terumo Corporation Acquires OrganOx Limited, thus entering into the organ transplantation-related sector, Biospace, August 24, 2025

Terumo, a leading medical technology company based in Japan, has announced a definitive agreement to acquire all outstanding shares of OrganOx, for approximately $1.5 billion. OrganOx specializes in advanced organ preservation devices using Normothermic Machine Perfusion technology, which preserves organs longer by circulating oxygen and nutrient-rich fluids through organs at near-body temperature. This technology enables

Terumo Corporation Acquires OrganOx Limited, thus entering into the organ transplantation-related sector, Biospace, August 24, 2025 Read Post »

“Breath Beyond Borders” Challenge, Pulmonary Vascular Research Institute (PVRI) – November 2025 PH Awareness Month

Members and supporters of the Pulmonary Vascular Research Institute (PVRI) are taking on a global challenge to raise awareness for pulmonary hypertension (PH). So far, 24 participants have pledged a combined 3,901 km (2,438 miles) — enough to travel from Athens to Dublin, crossing 12 countries! Why Dublin? The virtual “arrival” in Dublin is particularly

“Breath Beyond Borders” Challenge, Pulmonary Vascular Research Institute (PVRI) – November 2025 PH Awareness Month Read Post »

Global, Regional, and National Burden of Pulmonary Arterial Hypertension Among Women of Childbearing Age, 1990–2021, Pulmonary Circulation, August 20, 2025

This global study spanning from 1990 to 2021, published in Pulmonary Circulation, aimed to delineate the global burden of pulmonary arterial hypertension among women of childbearing age. The research reveals both encouraging and concerning trends. While mortality and disability rates have declined over the past three decades due to improved treatments, the absolute number of

Global, Regional, and National Burden of Pulmonary Arterial Hypertension Among Women of Childbearing Age, 1990–2021, Pulmonary Circulation, August 20, 2025 Read Post »